RE:RE:RE:Any company’s management team has a duty to maximize Apopis, IMO, this new relationship with a major deep pockets, respected medical research entity such as Li Ka Shing Institute substantially advances the possibility of some type of deal(JV/partnership/byout). Don't think for a second this Institution would be interested in this new relationship with little known Theralase if they wern't seriously impressed in the potential of their Act and/or the virus killing abilities of 1433, or both. It wouldn't surprise me at all if TLT never experienced another need to finance or a PP, when their associate had these financial capibilities, plus as their Research VP stated, "our facilities can accerate our partners path to market"
As to your question of would Theralase ever become a "large international pharmaceutical", my guess is no. If with the help of this Institute, if their Ph 2 trial can attain the CR% we think it can, a Big Pharma member like Merck would be forced to gobble it up before they lose market share to TLT.